Revisiting the 'cytokine storm' in ARDS; the painful wait for anti-inflammatory drugs/targets that solve Covid-19 deaths
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.
I am a pulmonary and critical care physician-scientist with substantial expertise in critical care medicine, particularly in the inflammatory pathways involved in the acute respiratory distress syndrome (ARDS) and ventilator-induced lung injury (VILI).
As a result, my laboratory has been pursuing mechanistic insights and effective therapies for ARDS and VILI for several decades. Over this expanded time horizon, there is abundant support for the contributory role of the much discussed “cytokine storm,” long associated with fatal ARDS and now with Covid-19-associated ARDS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.